The Motley Fool
19 Jul 2026, 22:10 UTC · 20h ago
Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
19 Jul 2026, 22:10 UTC · 20h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Johnson & Johnson increased its full-year sales guidance midpoint to $101.1 billion from $100.8 billion. — Raised revenue guidance typically signals confidence in growth and provides a positive catalyst for the stock price.
+0.40Growth in drugs Darzalex (up 18%) and Tremfya (up 72%) is offsetting the revenue loss from the loss of exclusivity of the blockbuster drug Stelara. — Demonstrates the company's ability to replace aging revenue streams with high-growth pharmaceutical products.
+0.30J&J's medtech division experienced weakness in Abiomed heart pump sales following a study questioning the use of Impella pumps in high-risk procedures. — Clinical concerns regarding a specific product line create a short-term headwind for the medtech segment.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company delivered a blowout earnings report, increased full-year forecasts, and showed strong growth in key pharmaceutical products.
Mentioned as a spin-off to boost J&J's growth, though no specific financial performance for Kenvue was detailed.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
2h ago
